JANX
Janux Therapeutics, Inc.
There isn't enough reported data to score JANX yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
JANX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Unavailable |
JANX's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
JANX PE Valuation
JANX has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
JANX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect JANX's losses to grow, with revenue declining. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
JANX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.59 | +$0.09 |
| Q2 2026 | -$1.64 | +$0.16 |
| Q1 2026 | -$1.84 | -$0.48 |
| Q4 2025 | -$1.83 | -$0.55 |
| Q3 2025 | -$1.68 | -$0.53 |
| Q2 2025 | -$1.80 | -$0.91 |
| Q1 2025 | -$1.36 | -$0.16 |
| Q4 2024 | -$1.28 | +$0.04 |
JANX lost $1.59 per share over the past year, about the same as its loss the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over JANX on earnings quality, reporting a profit while its opponent remains loss making.
JANX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.3M | -7.1% |
| Q3 2025 | $10M | +2178% |
| Q3 2024 | $439K | -83% |
| Q2 2024 | $8.9M | +742% |
| Q1 2024 | $1.3M | -39% |
| Q4 2023 | $2.5M | -13% |
| Q3 2023 | $2.5M | +39% |
| Q2 2023 | $1.1M | -55% |
JANX's revenue is growing: $9M last quarter, down 7.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -337% | +16 points |
| Q2 2026 | -309% | N/A |
| Q1 2026 | -917% | N/A |
| Q3 2025 | -353% | +7812 points |
| Q3 2024 | -8164% | -7536 points |
| Q2 2024 | -155% | +1808 points |
| Q1 2024 | -1610% | -620 points |
| Q4 2023 | -656% | -14 points |
JANX's operating margin was −337% last quarter, up 7828 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over JANX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over JANX on profitability, with a higher operating margin.
JANX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$25.2M | -$12.2M |
| Q2 2026 | $12.3M | +$36.6M |
| Q1 2026 | -$12.6M | +$4.8M |
| Q4 2025 | -$28.6M | -$11.9M |
| Q3 2025 | -$12.9M | -$10.7M |
| Q2 2025 | -$24.3M | -$14.2M |
| Q1 2025 | -$17.4M | -$2.4M |
| Q4 2024 | -$16.8M | -$6.4M |
JANX has burned cash in almost every quarter: −$54M over the past year, against −$71M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over JANX on cash generation, producing positive trailing cash flow while its opponent burns cash.
JANX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +153K shares |
| 1 year | +1.7% | +1.1M shares |
| 3 years | +38% | +17.4M shares |
| 5 years | +529% | +53.1M shares |
| Available history | +406% | +50.6M shares |
JANX has 63M diluted shares, up 1.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over JANX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
JANX Net Leverage
JANX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
JANX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.3 | Neutral |
| Stochastic | 34.0 | Neutral |
JANX's weekly RSI is 35 (neutral) and its Stochastic is 34 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
JANX PE vs Healthcare Sector
JANX has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
JANX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.4 | 30% below |
| 20 week MA | $16.6 | 31% below |
| 50 week MA | $15.1 | 24% below |
| 100 week MA | $22.7 | 49% below |
| 200 week MA | $24.7 | 53% below |
JANX is in a downtrend: it's below all five of its weekly moving averages, and 53% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over JANX on trend strength, trading above more of its moving averages.
JANX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $25.2 | $21.4 | -15% |
| 2022 | $21.4 | $11.9 | -45% |
| 2023 | $11.9 | $10.7 | -9.5% |
| 2024 | $10.7 | $54.1 | +404% |
| 2025 | $54.1 | $14.3 | -74% |
| 2026 YTD | $14.3 | $11.5 | -19% |
JANX's yearly returns have swung widely, from +404% in 2024 to −74% in 2025. It's down 19% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over JANX on returns for 2026, with the stronger performance.